Ann: Biochip moves toward feasibility & improved testing accuracy, page-9

I'm happy with the progress. I don't think the updates are overdone but price sensitive is another issue (many suggest governed by the asx?). They have to start somewhere with being able to refine their testing ability and repeatable accuracy. Perhaps first with standard solutions and then on to blood later. They have demonstrated their ability to refine things pretty quick, so I hope the next set of graphs show greater accuracy and repeatability. I like we are dealing with academics and tech people (I'm not one) but they are generally more focused on research and discovery, less on $ IMO. Lots of updates to come in the next 3-6 months. They did mention a big holder was selling down some time ago so maybe that's still happening. GLTA